Q32 Bio Inc. — Director's Dealing 2023

Jan 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2023-01-01

Reporting Person: Blum Michael Lee (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-01	Common Stock	M	2640	—	Acquired	11042	Direct
2023-01-01	Common Stock	M	4950	—	Acquired	15992	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-01	Restricted Stock Units	$	M	2640	Disposed		Common Stock (2640)	Direct
2023-01-01	Restricted Stock Units	$	M	4950	Disposed		Common Stock (4950)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.

F2: Includes 630 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2022 and 992 shares acquired under Issuer's Employee Stock Purchase Plan on August 31, 2022.

F3: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one half of the RSUs on each of January 1, 2023 and January 1, 2024. The RSUs do not have an expiration date.

F4: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date.